Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...

Amgen, which developed the drug in partnership with Belgium’s UCB, has come back with new data, and a request for approval in a narrower indication of women with osteoporosis at high risk of ...